Rani Therapeutics Holdings (RANI) Capital Expenditures (2020 - 2026)

Rani Therapeutics Holdings has reported Capital Expenditures for 7 years, with the latest figure at $32000.0 in Q2 2026.

• On a quarterly basis, Capital Expenditures fell 13.51% year-over-year to $32000.0 in Q2 2026; TTM through Jun 2026 was $47000.0, a 80.74% decrease from a year earlier, with the FY2025 full-year figure at $88000.0, down 67.16% from the prior year.
• Capital Expenditures was $32000.0 for Q2 2026 at Rani Therapeutics Holdings, up from $15000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $530000.0 in Q4 2022, with the low at $15000.0 in Q1 2026.
• Average Capital Expenditures over 5 years is $203187.5, with a median of $146000.0 recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Capital Expenditures soared 830.61% in 2022, then sank 81.44% in 2024.
• Over 5 years, Capital Expenditures stood at $530000.0 in 2022, then slumped by 68.49% to $167000.0 in 2023, then tumbled by 81.44% to $31000.0 in 2024, then increased by 19.35% to $37000.0 in 2025, then slipped by 13.51% to $32000.0 in 2026.
• The last three Capital Expenditures figures came in at $32000.0 (Q2 2026), $15000.0 (Q1 2026), and $37000.0 (Q2 2025), per Business Quant data.